https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Familial recurrence risks for multiple sclerosis in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13657 s) was similar across all sites. The familial recurrence risk of MS in Australia is lower than in previously reported studies. This is directly related to the lower population prevalence of MS. The overall genetic susceptibility in Australia as measured by the λs is similar to the northern hemisphere, suggesting that the difference in population risk is explained largely by environmental factors rather than by genetic admixture.]]> Sat 24 Mar 2018 08:25:18 AEDT ]]> Fluctuations of MS births and UV-light exposure https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18773 trend= 0.086). Conclusion: Seasonal fluctuation of MS births as found in this worldwide cohort of patients with MS did not correlate with variation in seasonal fluctuation of UV-light. Most likely, it results from a complex interplay between fluctuation of sunlight, behavioural factors, other environmental factors and (epi)genetic factors.]]> Sat 24 Mar 2018 07:51:09 AEDT ]]> BREMSO: a simple score to predict early the natural course of multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27967 Sat 24 Mar 2018 07:38:47 AEDT ]]> Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30017 Sat 24 Mar 2018 07:28:49 AEDT ]]> Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]>